L3VLUP
ProSign in

VTRS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VTRSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VTRS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterVTRSJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 202014 holders, $2.4bn32 holders, $26.6bn
Q1 202116 holders, $1.5bn31 holders, $25.3bn
Q2 20219 holders, $1.3bn37 holders, $25.6bn
Q3 202111 holders, $1.0bn40 holders, $24.1bn
Q4 202111 holders, $1.1bn33 holders, $25.2bn
Q1 20229 holders, $832m35 holders, $28.2bn
Q2 202213 holders, $1.0bn33 holders, $26.9bn
Q3 202212 holders, $714m36 holders, $25.4bn
Q4 202213 holders, $1.3bn35 holders, $27.6bn
Q1 202311 holders, $984m42 holders, $24.5bn
Q2 202313 holders, $1.1bn38 holders, $25.0bn
Q3 202313 holders, $1.1bn37 holders, $18.9bn
Q4 202310 holders, $1.1bn31 holders, $19.0bn
Q1 20248 holders, $1.3bn32 holders, $19.7bn
Q2 202412 holders, $1.1bn35 holders, $20.4bn
Q3 202413 holders, $1.2bn28 holders, $22.3bn
Q4 20249 holders, $1.4bn37 holders, $20.4bn
Q1 20259 holders, $819m32 holders, $20.5bn
Q2 202513 holders, $914m31 holders, $18.4bn
Q3 20259 holders, $1.1bn32 holders, $23.7bn
Q4 202510 holders, $1.3bn29 holders, $27.8bn
Q1 202613 holders, $1.4bn34 holders, $35.6bn
Q2 202612 holders, $3.1bn33 holders, $39.1bn
VTRS

Viatris Inc

Holders
9
Reported value
$819m
Buyers
6
Sellers
3

Breadth +3 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$20.5bn
Buyers
16
Sellers
15

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VTRS (4)

ExodusPoint Capital Management LP, Glenview Capital Management LLC, Greenlight Capital, Moore Capital Management LP

Only JNJ (27)

AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Two Sigma Advisers LP, Verition Fund Management LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →